Inflammatory Markers in Exhaled Breath (Condensate) in Childhood Asthma
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Nov 28, 2006
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Asthmatic and control children, aged 5 to 16 years
- • Children with doctor-diagnosed asthma, known at the department of Paediatric Pulmonology, University Hospital Maastricht
- Exclusion Criteria:
- • Presence of a disease that might interfere with the results of this study (e.g. recent upper airway infection, heart disease, anatomic abnormalities of the airways and other chronic inflammatory diseases such as Crohns disease and rheumatoid arthritis)
- • Mental retardation
- • Inability to perform the EBC procedure properly
- • Active smoking
- • The use of one of the following medication: Papaverin, Sodium nitroprusside, ACE inhibitors, Oxymetazoline, L-arginine, or NOS inhibitors
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Trial Officials
Charlotte M Robroeks, MD
Principal Investigator
Maastricht University Medical Center
Edward Dompeling, MD, PhD
Study Director
Maastricht University Medical Center
Quirijn Jöbsis, MD, PhD
Study Director
Maastricht University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials